TS/A is a spontaneous adenocarcinoma, apparently not immunogenic in BALB/cnAnCr mice. TS/A cells are unable to stimulate a syngeneic antitumor response either in vitro or in vivo. To evaluate the immunogenic potential of IL-2-releasing neoplastic cells, we used an expression vector to introduce the cDNA coding for murine IL-2 into TS/A cells. Six clones releasing between 30 and 6800 U of IL-2/10(5) cells/ml/48 h have been isolated. Both low (30 U, B1.30) and high (6000 U, B4.6000) IL-2-releasing clone are capable of stimulating a proliferative and cytotoxic response in syngeneic cultures. While the B1.30 clone grows in 60% of syngeneic mice with a delayed pattern, the five clones that release higher levels of IL-2 are promptly rejected. Rej...
HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-oncogene, develop spo...
Previous studies have shown that expression of the immune co-stimulator B7.1 reduces the tumorigenic...
This study involved the conversion of class II MHC negative tumour cells, via transduction with the ...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Here we demonstrate that the murine mammary adenocarcinoma cell line TS/A, a highly malignant MHC-II...
The MCA 102 sarcoma has been defined by a variety of immunologic studies as a tumor lacking intrinsi...
Purpose: We have shown previously that the MHC class II - negative murineTS/A adenocarcinoma is reje...
Vaccination with a poorly or not immunogenic tumor fails to protect the host from a subsequent chall...
Tumor-infiltrating lymphocytes (TIL) are found in most human infiltrating ductal breast carcinomas. ...
International audienceResponsiveness to IL-2 varies from one lympho-mononuclear subset to another. N...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
Nylon wool columns eluting lymphocytes from the spleen of mice bearing a clinically evident spontane...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
Attempts to cure breast cancer by adoptive cellular therapy (ACT) have not been successful. This is ...
The potential of interleukin 2-gene-transfected tumor cells to prevent tumor growth and cure establi...
HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-oncogene, develop spo...
Previous studies have shown that expression of the immune co-stimulator B7.1 reduces the tumorigenic...
This study involved the conversion of class II MHC negative tumour cells, via transduction with the ...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Here we demonstrate that the murine mammary adenocarcinoma cell line TS/A, a highly malignant MHC-II...
The MCA 102 sarcoma has been defined by a variety of immunologic studies as a tumor lacking intrinsi...
Purpose: We have shown previously that the MHC class II - negative murineTS/A adenocarcinoma is reje...
Vaccination with a poorly or not immunogenic tumor fails to protect the host from a subsequent chall...
Tumor-infiltrating lymphocytes (TIL) are found in most human infiltrating ductal breast carcinomas. ...
International audienceResponsiveness to IL-2 varies from one lympho-mononuclear subset to another. N...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
Nylon wool columns eluting lymphocytes from the spleen of mice bearing a clinically evident spontane...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
Attempts to cure breast cancer by adoptive cellular therapy (ACT) have not been successful. This is ...
The potential of interleukin 2-gene-transfected tumor cells to prevent tumor growth and cure establi...
HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-oncogene, develop spo...
Previous studies have shown that expression of the immune co-stimulator B7.1 reduces the tumorigenic...
This study involved the conversion of class II MHC negative tumour cells, via transduction with the ...